 Connection
Alan Gamis to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Alan Gamis has written about Randomized Controlled Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.627 |
|
|
|
-
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 08 17; 130(7):943-945.
Score: 0.575
-
Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43.
Score: 0.033
-
Sung L, Alibhai SM, Beyene J, Gamis A, Almeida R, Smith S, Aplenc R. Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. Leukemia. 2009 Apr; 23(4):811-3.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|